Difference between revisions of "Rhabdomyosarcoma"
Jump to navigation
Jump to search
m |
|||
Line 32: | Line 32: | ||
|- | |- | ||
|2. [[#VIE|VIE]] | |2. [[#VIE|VIE]] | ||
+ | | style="background-color:#ffffbf" |Seems not superior | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145831/ Hawkins et al. 2018 (ARST0531)] | ||
+ | | style="background-color:#1a9851" |Phase III (C) | ||
+ | |VAC/VI | ||
| style="background-color:#ffffbf" |Seems not superior | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
Line 43: | Line 48: | ||
===References=== | ===References=== | ||
# '''IRS-IV:''' Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.12.3091 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11408506 PubMed] | # '''IRS-IV:''' Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.12.3091 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11408506 PubMed] | ||
+ | # '''ARST0531:''' Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. Epub 2018 Aug 9. [http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9694 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145831/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30091945 PubMed] | ||
==VAI {{#subobject:9ab538|Regimen=1}}== | ==VAI {{#subobject:9ab538|Regimen=1}}== |
Revision as of 01:50, 3 October 2018
Section editor | |
---|---|
James L. Chen, MD, MS Columbus, OH |
4 regimens on this page
4 variants on this page
|
All lines of therapy
VAC
back to top |
VAC: Vincristine, Actinomycin D, Cyclophosphamide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Crist et al. 2001 (IRS-IV) | Phase III (E) | 1. VAI | Seems not superior |
2. VIE | Seems not superior | ||
Hawkins et al. 2018 (ARST0531) | Phase III (C) | VAC/VI | Seems not superior |
To be completed
Chemotherapy
References
- IRS-IV: Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. link to original article PubMed
- ARST0531: Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. Epub 2018 Aug 9. link to original article link to PMC article PubMed
VAI
back to top |
VAI: Vincristine, Actinomycin-D (Dactinomycin), Ifosfamide
IVA: Ifosfamide, Vincristine, Actinomycin-D (Dactinomycin)
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Crist et al. 2001 (IRS-IV) | Phase III (E) | 1. VAC | Seems not superior |
2. VIE | Seems not superior | ||
Oberlin et al. 2012 (SIOP MMT95) | Phase III (C) | IVA/CEV/IVE | Seems not superior |
Bisogno et al. 2018 (EpSSG RMS 2005) | Phase III (C) | IVA-D, then IVA | Seems not superior |
To be completed
Chemotherapy
References
- IRS-IV: Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. link to original article PubMed
- SIOP MMT95: Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012 Jul 10;30(20):2457-65. Epub 2012 Jun 4. link to original article PubMed
- EpSSG RMS 2005: Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018 Aug;19(8):1061-1071. Epub 2018 Jun 22. link to original article PubMed
VI, then VDC/IE, then VAC, then VI
back to top |
VI, then VDC/IE, then VAC, then VI: Vincristine & Irinotecan, followed by Vincristine, Doxorubicin, Cyclophosphamide alternating with Ifosfamide & Etoposide, followed by Vincristine, Actinomycin D, Cyclophosphamide, followed by Vincristine & Irinotecan
Regimen
Study | Evidence |
---|---|
Weigel et al. 2015 (COG ARST0431) | Phase II |
Note: this is a complicated 54-week regimen with no immediate plans to add it to HemOnc.org. Please refer to the original article.
References
- Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CA. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol. 2016 Jan 10;34(2):117-22. Epub 2015 Oct 26. link to original article link to PMC article PubMed
VIE
back to top |
VIE: Vincristine, Ifosfamide, Etoposide
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Crist et al. 2001 (IRS-IV) | Phase III (E) | 1. VAC | Seems not superior |
2. VAI | Seems not superior |
To be completed
Chemotherapy
References
- IRS-IV: Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001 Jun 15;19(12):3091-102. link to original article PubMed